{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:28:05Z","timestamp":1790519285129,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,5,23]],"date-time":"2005-05-23T00:00:00Z","timestamp":1116806400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p>\n                    <jats:bold>Abstract:\u2002<\/jats:bold>\n                    Infliximab, a chimeric antitumor necrosis factor alpha monoclonal antibody (anti\u2010TNF \u03b1), has been recently shown to have a beneficial effect on pyoderma gangrenosum associated with inflammatory bowel disease. Patients with the syndromic triad of pyogenic sterile arthritis, pyoderma gangrenosum, and acne, an autoinflammatory process caused by mutations in the CD2 binding protein\u20101 (\n                    <jats:italic>CD2BP1<\/jats:italic>\n                    ) gene, can have severe pyoderma gangrenosum. We describe a 14\u2010year\u2010old patient with this syndrome who was unresponsive to multiple therapies. A dramatic improvement in his pyoderma gangrenosum was observed after one infusion of infliximab, and a second infusion led to its resolution. Our observation extends the therapeutic use of infliximab to this component of PAPA syndrome.\n                  <\/jats:p>","DOI":"10.1111\/j.1525-1470.2005.22320.x","type":"journal-article","created":{"date-parts":[[2005,5,23]],"date-time":"2005-05-23T04:31:04Z","timestamp":1116822664000},"page":"262-265","source":"Crossref","is-referenced-by-count":114,"title":["Dramatic Improvement of Pyoderma Gangrenosum with Infliximab in a Patient with PAPA Syndrome"],"prefix":"10.1111","volume":"22","author":[{"given":"Dorothee S.","family":"Stichweh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilynn","family":"Punaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,5,23]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.8.961"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.4065\/72.7.611"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/302866"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<2041::AID-ANR15>3.0.CO;2-G"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.24.7320"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2135380100"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00516-2"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655202320378338"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/713786537"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01092.x"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065860"},{"key":"e_1_2_4_13_2","first-page":"930","article-title":"Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti\u2010tumor necrosis factor alpha monoclonal antibody","volume":"137","author":"Tan MH","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70132-6"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.135.5.564"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200205000-00016"},{"issue":"11","key":"e_1_2_4_17_2","first-page":"2315","article-title":"Do clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor\u2010alpha antagonists in patients with rheumatoid arthritis?","volume":"30","author":"Ang HTS","year":"2003","journal-title":"J Rheumatol"},{"issue":"9","key":"e_1_2_4_18_2","first-page":"S81","article-title":"Safety and efficacy of infliximab therapy after etanercept failure: a case series","volume":"44","author":"Shergy WJ","year":"2001","journal-title":"Arthritis Rheum"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.10.1441"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-1470.2005.22320.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-1470.2005.22320.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T21:55:14Z","timestamp":1697147714000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-1470.2005.22320.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1525-1470.2005.22320.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-1470.2005.22320.x","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}